| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| MORGAN STANLEY | 3.2% | -65% | $15,327,382 | -$22,120,527 | 13,213,260 | -59.1% | Morgan Stanley | 31 Jul 2025 |
| OrbiMed Israel BioFund GP Limited Partnership | 4.8% | $1,328,636 | 969,807 | ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP | 18 Jun 2025 | |||
| SPHERA FUNDS MANAGEMENT LTD. | 4.78% | $1,152,548 | 900,428 | Sphera Funds Management Ltd. | 31 Mar 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 0 | $0 | -$4,891,584 | 0 | |
| 2025 Q2 | 4,230,788 | $4,907,708 | +$580,031 | $1.16 | 14 |
| 2025 Q1 | 3,731,679 | $4,067,948 | -$471,792 | $1.09 | 17 |
| 2024 Q4 | 4,160,723 | $7,530,756 | -$700,297 | $1.81 | 16 |
| 2024 Q3 | 4,549,767 | $7,142,810 | +$3,023,403 | $1.57 | 15 |
| 2024 Q2 | 2,672,756 | $2,441,306 | +$15,800 | $0.9125 | 15 |
| 2024 Q1 | 2,661,598 | $2,073,381 | -$89,384 | $0.779 | 14 |
| 2023 Q4 | 2,813,782 | $1,434,861 | +$143,796 | $0.51 | 16 |
| 2023 Q3 | 2,530,576 | $2,264,861 | -$524 | $0.895 | 11 |
| 2023 Q2 | 2,531,115 | $3,327,272 | -$562,185 | $1.32 | 10 |
| 2023 Q1 | 2,889,758 | $4,560,246 | -$695,559 | $1.59 | 12 |
| 2022 Q4 | 3,313,486 | $10,603,060 | +$239,615 | $3.2 | 13 |
| 2022 Q3 | 3,249,704 | $8,092,000 | -$130,379 | $2.49 | 13 |
| 2022 Q2 | 3,288,318 | $12,166,000 | -$114,849 | $3.7 | 13 |
| 2022 Q1 | 3,307,612 | $15,880,000 | -$99,757 | $4.79 | 15 |
| 2021 Q4 | 3,288,041 | $22,686,000 | +$310,558 | $6.9 | 14 |
| 2021 Q3 | 3,241,493 | $35,915,000 | +$733,108 | $11.08 | 13 |
| 2021 Q2 | 3,085,723 | $58,690,000 | +$1,761,108 | $19.02 | 11 |
| 2021 Q1 | 2,876,992 | $82,600,000 | +$82,600,000 | $28.74 | 10 |